semaglutide Peptide China 99%Purity White Lyophilized powder 10vial/box

Product: Semaglutide

· Specification: 2mg/vial, 5mg/vial, 10mg/vial,15mg/vial,20mg/vial,30mg/vial (optional)
· Packaging: 10 vials per box
· Form: Sterile lyophilized powder (purity >99%)
· Usage: Reconstitute with bacteriostatic water before subcutaneous . Recommended once per week under professional guidance.
· Storage:
· Before reconstitution: Store at room temperature (avoid direct sunlight)
· After reconstitution: Refrigerate (2–8°C). Follow medical advice or research guidelines for usage period.
· Price: Please contact the supplier (price varies by specification and order quantity)
· Shipping: Depends on quantity, destination, and customs policies. Typically $80 for up to 5 boxes to the US/Australia. Delivery time: 7–14 days.

What it is used for:
Semaglutide is a GLP-1 receptor agonist. It has been approved by the FDA and NMPA for the following indications:

1. Type 2 Diabetes Mellitus

· Improves blood sugar control in adults with type 2 diabetes
· Can be used alone or in combination with other antidiabetic medications (e.g., metformin, SGLT2 inhibitors, insulin)
· Reduces HbA1c by up to 1.5%–1.8%

2. Weight Management

· For chronic weight management in adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia)
· At 68 weeks, the 2.4mg group achieved an average weight loss of 14.9% (approximately 15–18 kg)
· Reduces waist circumference, body fat percentage, and visceral fat

3. Cardiovascular Protection

· Reduces the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke
· Benefit is particularly significant in patients with type 2 diabetes and established cardiovascular disease
· Lowers systolic blood pressure and inflammatory markers (e.g., hs-CRP)

4. Non-Alcoholic Fatty Liver Disease (NAFLD)

· Reduces liver fat content
· Improves liver function markers (e.g., ALT, AST)
· Some studies suggest it may slow the progression of liver fibrosis

5. Chronic Kidney Disease (CKD)

· May slow the decline in kidney function (reduces urinary protein excretion rate)
· Potential benefit for patients with type 2 diabetes and CKD

6. Polycystic Ovary Syndrome (PCOS)

· Improves insulin resistance and reduces body weight
· May help restore menstrual cycles and improve metabolic markers (more research needed)

Target audience (for reference only):

· Patients with type 2 diabetes
· Adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbidity
· Patients with type 2 diabetes and established cardiovascular disease
· Patients with non-alcoholic fatty liver disease (NAFLD)
· Patients with polycystic ovary syndrome (PCOS) — under physician evaluation
· Must be used under the guidance of a physician

Important notes:

· Boxed Warning: Contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
· Common side effects: Nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, indigestion. Mostly mild to moderate, typically diminish over time.
· Serious adverse reactions:
· Acute pancreatitis (discontinue and seek medical attention if persistent severe abdominal pain occurs)
· Gallbladder disease (cholelithiasis, cholecystitis)
· Hypoglycemia (especially when combined with sulfonylureas or insulin)
· Acute kidney injury (rare, mostly due to dehydration from severe gastrointestinal reactions)
· Diabetic retinopathy complications
· Not recommended for pregnant or breastfeeding women, individuals with severe gastrointestinal disorders, or those with a history of pancreatitis
· Prescription drug. Must be used under the supervision of a physician.